In addition, we discuss the rationale for a therapeutic strategy aiming at inhibiting NOTCH1 signaling in CLL, along with an overview on the currently available NOTCH1-directed approaches. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.